Unfavorable response to capmatinib for MET exon14 skipping after first-line osimertinib in a patient with EGFR-mutated lung adenocarcinoma: A case report and literature review

IF 2.4 Q2 RESPIRATORY SYSTEM
Taisuke Araki , Shintaro Kanda , Tatsuya Yazaki , Taro Hirabayashi , Masamichi Komatsu , Kei Sonehara , Kazunari Tateishi , Masayuki Hanaoka
{"title":"Unfavorable response to capmatinib for MET exon14 skipping after first-line osimertinib in a patient with EGFR-mutated lung adenocarcinoma: A case report and literature review","authors":"Taisuke Araki ,&nbsp;Shintaro Kanda ,&nbsp;Tatsuya Yazaki ,&nbsp;Taro Hirabayashi ,&nbsp;Masamichi Komatsu ,&nbsp;Kei Sonehara ,&nbsp;Kazunari Tateishi ,&nbsp;Masayuki Hanaoka","doi":"10.1016/j.resinv.2024.05.009","DOIUrl":null,"url":null,"abstract":"<div><p><em>MET</em> exon14 skipping mutations (<em>MET</em>ex14s) are rarely reported as a potential resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs). The efficacy of targeted therapy against <em>MET</em>ex14s emerging after osimertinib resistance is uncertain. Herein, we report a case of <em>EGFR-</em>mutated metastatic lung adenocarcinoma in which <em>MET</em>ex14 was detected in a re-biopsy upon first-line osimertinib resistance. The patient received capmatinib monotherapy as third-line therapy, which was ineffective, followed by an exceptional response to salvage therapy with afatinib. This report highlights the heterogeneity of EGFR-TKI resistance and that targeting rare resistance mechanisms remains challenging.</p></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"62 4","pages":"Pages 677-680"},"PeriodicalIF":2.4000,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory investigation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212534524000844","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

MET exon14 skipping mutations (METex14s) are rarely reported as a potential resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs). The efficacy of targeted therapy against METex14s emerging after osimertinib resistance is uncertain. Herein, we report a case of EGFR-mutated metastatic lung adenocarcinoma in which METex14 was detected in a re-biopsy upon first-line osimertinib resistance. The patient received capmatinib monotherapy as third-line therapy, which was ineffective, followed by an exceptional response to salvage therapy with afatinib. This report highlights the heterogeneity of EGFR-TKI resistance and that targeting rare resistance mechanisms remains challenging.

一名表皮生长因子受体(EGFR)突变肺腺癌患者在一线奥西美替尼治疗后对卡帕替尼治疗MET外显子14缺失的不良反应:病例报告和文献综述
作为表皮生长因子受体酪氨酸激酶抑制剂(TKIs)的一种潜在耐药机制,MET外显子14跳跃突变(METex14s)鲜有报道。针对奥希替尼耐药后出现的METex14s的靶向治疗疗效尚不确定。在此,我们报告了一例表皮生长因子受体(EGFR)突变的转移性肺腺癌患者,该患者在一线奥希替尼耐药后再次活检时发现了METex14。该患者接受了卡帕替尼单药作为三线治疗,但效果不佳,随后对阿法替尼的挽救治疗产生了特殊反应。该报告强调了表皮生长因子受体-TKI耐药的异质性,以及针对罕见耐药机制的靶向治疗仍具有挑战性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Respiratory investigation
Respiratory investigation RESPIRATORY SYSTEM-
CiteScore
4.90
自引率
6.50%
发文量
114
审稿时长
64 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信